David Solomon News
-
Goldman Sachs Group Inc., which has been advising Apple Inc. on how to deal with its multibillion- dollar cash pile, and Deutsche Bank AG, Germany’s biggest lender, are in the lead to help the iPhone maker sell bonds for the first time in 17 years.
-
Forest Laboratories Inc., maker of the antidepressant drug Lexapro, urged investors to ignore Carl Icahn’s attempt to get four nominees elected to the board.
-
Lloyd C. Blankfein nuzzled his beard against the cheeks of two ladies last night, Dina Powell, Goldman Sachs Group Inc.’s head of corporate engagement, and Liz Robbins, a Democratic lobbyist.
-
For investment bankers, 2011 started with a shout and ended with a whimper -- causing fees to shoot up in the first half, then fizzle at year’s end.
-
Sanofi defended its experimental drug Lyxumia after some scientists questioned the medicine’s novelty at a diabetes conference.
-
The 10th annual Tribeca Film Institute Inc. benefit last night began with a screening of “New Year’s Eve” at the Ziegfeld Theatre and ended in the ballroom of the Hilton New York, where guests mingled with stars around replicas of the Times Square New Year’s Eve ball.
-
Investors are turning to hedge funds such as Caxton Associates LLC that don’t have restrictions on withdrawals when making new commitments, according to a new survey of fund clients.
-
Goldman Sachs Group Inc., the world’s top-ranked mergers and acquisitions adviser this year, named Gregg Lemkau to help lead that business worldwide and put Gilberto Pozzi in Lemkau’s prior role running M&A in Europe.
-
Goldman Sachs Group Inc. appointed James P. Esposito , who worked in the debt capital markets unit, to succeed Howard Schiller as chief operating officer of the firm’s investment-banking division, according to an internal memo.
-
Zealand Pharma A/S , the Danish drugmaker developing a diabetes medicine with Sanofi-Aventis SA, raised a net 321 million kroner ($58 million) in its initial public stock offering, a third of what it originally targeted.
|
|
Most Popular on Bloomberg
|
| |
Rate this Page